Elicio Therapeutics Inc (ELTX)
7.88
+0.37
(+4.93%)
USD |
NASDAQ |
May 31, 16:00
7.90
+0.02
(+0.25%)
After-Hours: 20:00
Elicio Therapeutics Research and Development Expense (Quarterly): 7.559M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 7.559M |
| December 31, 2023 | 6.157M |
| September 30, 2023 | 7.264M |
| June 30, 2023 | 4.944M |
| March 31, 2023 | 5.484M |
| Date | Value |
|---|---|
| December 31, 2022 | 4.29M |
| September 30, 2022 | 4.593M |
| June 30, 2022 | 5.041M |
| March 31, 2021 | 4.554M |
| March 31, 2020 | 2.376M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.376M
Minimum
Mar 2020
7.559M
Maximum
Mar 2024
5.226M
Average
4.992M
Median
Research and Development Expense (Quarterly) Benchmarks
| Immuneering Corp | 11.20M |
| Outlook Therapeutics Inc | 13.51M |
| Amylyx Pharmaceuticals Inc | 36.61M |
| NovaBay Pharmaceuticals Inc | 0.019M |
| Palatin Technologies Inc | 7.160M |